

Immuron

Fax

To: ASX Company Announcement From: G. Rawlin
Fax: 1300 136138 Office Pages: 4
Phone: _____ Date: _____
Re: ASX Letter following CC: _____

☐ Urgent ☐ For Review ☐ Please Comment ☐ Please Reply ☐ Please Recycle

Title: Clinical trial approved in USA for
Immuron's adjunctive therapy for HIV.

ABN 80 063 114 045
AUSTRALIA
Level 1, 39 Leveson Street
North Melbourne VIC 3051
Tel (61) 3 9018 4880 Fax (61) 3 9018 4881

USA
The Empire State Building
350 Fifth Avenue 59th Floor
New York, N.Y. 10118
Tel 646 402 5289 Fax 646 390 3238



Formally Anadis Limited

13 January 2009,

The Manager
The Company Announcement Office
Australian Stock Exchange Limited
Sydney, NSW

Dear Sir,

Clinical Trial approved in USA for Immuron's adjunctive therapy for HIV

Attached is an announcement in respect of the approval of a Phase 2 human clinical study in HIV/AIDS patients at a US AIDS research centre. The announcement also contains information about the winning of a research grant with University of Melbourne to further develop further antibody products in the area of HIV control.

Yours faithfully

A handwritten signature in black ink, appearing to read "Dr Grant Rawlin".

Dr Grant Rawlin
General Manager,
VP, Research and Development

ABN 80 063 114 045
AUSTRALIA
Level 1, 39 Leveson Street
North Melbourne VIC 3051
Tel (61) 3 9018 4880 Fax (61) 3 9018 4881

USA
The Empire State Building
350 Fifth Avenue 59th Floor
New York, N.Y. 10118
Tel 646 402 5289 Fax 646 390 3238

Immuron

Immuron Ltd. Announces Phase II trial of BioGard in U.S., its oral antibody adjunctive -HIV therapy; wins research grant for an HIV antibody

January 13, 2009

San Francisco and Melbourne, Australia---Immuron Ltd. (ASX: IMC), a biopharmaceutical company specializing in oral immunotherapy development and antibody manufacturing, announces today approval for a Phase II human clinical study in HIV/AIDS patients at a prestigious U.S. AIDS research center. The announcement was made during the 27th Annual J.P. Morgan Healthcare Conference in San Francisco.

The study is being conducted by the Center for AIDS Research, a prominent NIH funded research program, at Case Western Reserve University. University Hospitals in Cleveland Ohio. The study is led by Professors Gopal Yadavalli, Benigno Rodriguez and Michael Lederman, Associate Director of the Center. The study aims to document the ability of Immuron's BioGard™ hyperimmune bovine colostrum powder formulation to decrease translocation of gut-derived microbial products and decrease immune activation in patients with early stage HIV infection. BioGard contains a mixture of anti-LPS and other antibodies active at the mucosal surface. The study will begin in calendar Q1 2009 and positive results could open a window to expanded trials of BioGard as part of routine HIV/AIDS therapy regimens.

The study complements a recently announced multi-site clinical trial beginning in Australia examining the product's efficacy in HIV/AIDS patients undergoing intensified therapy for persistent immune activation.

Dr. Zeil Rosenberg, Immuron CEO, stated, "We are thrilled with the interest that the Center for AIDS Research has in initiating this study so rapidly. We are even more hopeful now that our oral antibodies can create a new paradigm for addressing an emerging need in HIV patient care."

Separately, Immuron announces that Associate Professor Damian Purcell, Head of the Molecular Virology Laboratory at the University of Melbourne, working with the

Australian Centers for HIV and Hepatitis Virology, has been awarded a research grant by the Australian Department of Health and Aging to develop and test an Immuron produced hyperimmune colostrum powder formulation containing antibodies against HIV envelope antigens. This project will augment a new research collaboration with the US National Institutes for Health (NIH). Dr. Oren Fuerst, VP Business development of Immuron stated: "Our unique technology platform allows for the rapid development of targeted antibodies. In addition to targeting HIV related inflammation, we are now developing antibodies against the virus causing AIDS itself."

Immuron Limited (IMC.AX) (formerly called Anadis) is a biopharmaceutical company focused on antigen-primed, dairy-derived health products. Immuron's proprietary and antibody manufacturing technology enables it to rapidly develop polyclonal antibody and other protein-based oral therapies to a range of important infectious and immune-mediated diseases, including Influenza, Oral and GI tract Mucositis, and HIV related inflammation.

Contact:

Dr. Oren Fuerst- VP, Business Development

Email: oren@immuron.com

Tel +1 646 259 3321

Arie Nudel- Investor Relations

Email: arie@immuron.com

Tel: +61 3 9014 4880